bioAffinity
  • Home
  • Publications
  • News
  • About Us
  • Videos
  • Contact
  • Investor Relations
  • Careers
Select Page

Meet BioAffinity Technologies: Fly exclusive interview with CEO Maria Zannes

by Dale Harrison | Dec 28, 2022 | Articles, News

Meet BioAffinity Technologies: Fly exclusive interview with CEO Maria Zannes DECEMBER 28, 2022 As published in the The Fly By: Jessica de Sa-Mota BioAffinity focuses on the development of noninvasive, early-stage cancer diagnosis and targeted cancer treatment In an...

SA Cancer Diagnostic Company Adding Research Talent

by Dale Harrison | Dec 23, 2022 | Articles, News

SA Cancer Diagnostic Company Adding Research Talent DECEMBER 23, 2022 As published in the San Antonio Business Journal By: W. Scott Bailey – Senior Reporter, San Antonio Business Journal BioAffinity Technologies Inc. is making multiple personnel moves in an effort to...

Maria Zannes named to TEXAS 100 Influential professionals to watch in 2023

by Dale Harrison | Dec 21, 2022 | Articles, News

TEXAS 100 Influential professionals to watch in 2023 DECEMBER 21, 2022 As published in the San Antonio Business Journal By: Colin Pope – Editor, Austin Business Journal Our annual Texas 100 is a list of impactful Texans who will likely play crucial roles in the...

After going public, SA company charts next course

by Dale Harrison | Nov 29, 2022 | Articles, News

After going public, SA company charts next course NOVEMBER 29, 2022 As published in the San Antonio Business Journal By: W. Scott Bailey – Senior Reporter, San Antonio Business Journal Fresh off of filing its first earnings report as a publicly traded company, San...

San Antonio cancer biotech follows IPO with patent win in China

by Dale Harrison | Nov 2, 2022 | Articles, News

San Antonio cancer biotech follows IPO with patent win in China NOVEMBER 2, 2022 As published in the San Antonio Business Journal By: By W. Scott Bailey – Senior Reporter, San Antonio Business Journal The People’s Republic of China has awarded a Certificate of Patent...

Behind the Deal: Company’s decision to go public drawing capital and attention to SA

by Dale Harrison | Sep 30, 2022 | Articles, News

Behind the Deal: Company’s decision to go public drawing capital and attention to SA SEPTEMBER 30, 2022 As published in the San Antonio Business Journal By: W. Scott Bailey – Senior Reporter, San Antonio Business Journal The move by bioAffinity Technologies Inc. to...
« Older Entries
Next Entries »

Categories

  • Articles (27)
  • Events (38)
  • News (52)
  • Press Releases (131)
  • Publications (17)

Recent Posts

  • Case Study: CyPath® Lung Detects Stage 1A Lung Cancer in High-Risk Patient with Inconclusive Imaging and Low-Risk Serum Test Results July 29, 2025
  • Case Study: CyPath® Lung Detects Neuroendocrine Tumor Missed by Other Diagnostic Tools July 23, 2025
  • Canada Awards New Patent to bioAffinity Technologies for CyPath® Lung, Company’s Noninvasive Lung Cancer Diagnostic July 22, 2025
  • bioAffinity Technologies Announces Notification of China Patent Award for Company’s Noninvasive Lung Cancer Diagnostic July 15, 2025
  • Case Study: CyPath® Lung Detects Stage 1A Lung Cancer in High-Risk Patient with Inconclusive Imaging July 9, 2025

Learn About CyPath Lung

CyPath Lung Test

Main Menu

  • Home
  • Publications
  • News
  • About Us
  • Videos
  • Contact
  • Investor Relations
  • Careers
Copyright © 2023 bioAffinity Technologies, Inc.